Millstone Medical Oursourcing, LLC is announcing that going forward it will be working with ImplantBase, LLC, a web-based software platform for medical device field inventory management.
Millstone, ImplantBase Announce Strategic Relationship

“The prospect of working with the ImplantBase team to provide customers with a true end to end solution for their inventory is one that excites us, ” said Tom Williams, SVP at Millstone Medical, in the January 11, 2016 news release. “The capabilities of ImplantBase to manage and gain visibility to field inventory when coupled with Millstone’s services provide a real differentiator to medical device manufacturers.”
Ethan Lauer, CEO at ImplantBase continued “Our relationship with Millstone Medical provides us an opportunity to advance our vision for the medical device industry where field sales reps and operations people are digitally connected to the entire supply chain anywhere, anytime. This relationship is the next step to solving the very expensive ‘last-mile logistics’ inventory problem that has plagued the medical device industry for decades; we are thrilled to be part of it.”
Asked what led to this, Tom Williams told OTW, “It was a conversation highlighting the fact that both organizations share a vision to streamline the inventory management and delivery model as it stands in the orthopedic sector today, and that our services are complementary to realizing the vision.”
Asked about challenging days ahead, Williams added, “The most challenging days will also be the most fun; understanding the pain points of each unique customer and applying solutions to those problems that benefit their entire organization be it the supply chain or sales organization.”

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.